Source comparison
Regulatory Status: Research Compound vs Approved Medication
The fundamental difference between Vyleesi and PT-141 is FDA oversight. Vyleesi underwent Phase III clinical trials (RECONNECT study, published in JAMA Internal Medicine, 2019) enrolling 1,247 premenopausal women with HSDD. The trial demonstrated statistically
This comparison does not assign a generated winner or score.
- The fundamental difference between Vyleesi and PT-141 is FDA oversight. Vyleesi underwent Phase III clinical trials (RECONNECT study, published in JAMA Internal Medicine, 2019) enrolling 1,247 premenopausal women with HSDD. The trial demonstrated statistically significant improvement in sexual desire and reduction in distress compared to placebo. Mean change in eDiary sexual desire score was +0.3 vs +0.2 placebo (p<0.001).
- PT-141, conversely, refers to the investigational compound used during preclinical and early-phase research. Material sold under the PT-141 designation today typically originates from research chemical suppliers or peptide synthesis labs. Not FDA-registered pharmaceutical manufacturers. These sources operate under different quality frameworks: research-grade peptides are synthesised for laboratory use, often with purity verification by HPLC (high-performance liquid chromatography) but without the batch consistency, sterility testing, or endotoxin screening required for human pharmaceutical use.
- This distinction creates a safety gap. Vyleesi is manufactured by AMAG Pharmaceuticals under FDA-mandated cGMP standards. Every production batch undergoes potency assay, sterility confirmation, and pyrogenicity testing before release. PT-141 purchased from research suppliers may be chemically identical at the molecular level but lacks traceability: if contamination occurs or the peptide degrades during storage, there is no regulatory framework requiring disclosure or recall.
- One critical compliance point: prescribing Vyleesi requires an FDA-approved indication (HSDD in premenopausal women). Off-label use for male sexual dysfunction or other indications falls outside the approved labelling. PT-141 is not legally prescribable as a medication. It exists in a regulatory gray zone as a research chemical, not a pharmaceutical product.